Jennifer Penberthy

This presentation synthesizes clinical case studies, phenomenological reports, and emerging neuroimaging data to challenge conventional brain- and body-centered models of mind, grief, and recovery. Central to the discussion is the phenomenon of after-death communication (ADC). A compelling case study illustrates a grieving partner who, through daily mindfulness meditation, experienced a veridical, loving ADC six months post-loss. This spontaneous perceptual event—characterized by vivid sensory presence and emotional reciprocity—precipitated profound resolution of prolonged grief disorder (PGD) symptoms, including yearning, intrusive rumination, and identity disruption. Such experiences align with DOPS archival data documenting ADCs as non-pathological, transformative phenomena that correlate with accelerated bereavement adaptation and enhanced well-being. Complementing meditation-based ADC, recent psilocybin-assisted psychotherapy trials reveal parallel mechanisms. A narrative review of controlled studies demonstrates that single-dose psilocybin, paired with preparatory and integrative psychological support, reliably induces mystical-type experiences marked by transcendence, ego dissolution, and unitive consciousness. These states disrupt maladaptive grief schemas, foster emotional catharsis, and promote narrative reconstruction of the deceased relationship. Preliminary evidence suggests psilocybin may be uniquely efficacious for PGD, a condition often refractory to conventional antidepressants or exposure-based therapies. To ground phenomenological reports in neurobiology, we present novel fMRI findings from an ongoing randomized trial. Pre- and post-psilocybin scans during grief-elicitation tasks (e.g., viewing photographs of the deceased) and cognitive paradigms (e.g., emotional Stroop, working memory) reveal significant modulation of the default mode network (DMN), salience network, and amygdala-prefrontal connectivity. Post-intervention, participants exhibit reduced DMN hyperconnectivity—a putative neural signature of rumination—and enhanced top-down emotion regulation, mirroring changes observed in long-term meditators. These objective markers provide a mechanistic bridge between subjective transcendence and durable therapeutic outcomes. Beyond grief, the convergence of meditation and psilocybin points to a broader paradigm: intentional induction of expanded consciousness as a therapeutic modality. By transiently suspending embodied self-boundaries, these interventions access transpersonal dimensions of mind that may underpin resilience, meaning-making, and post-traumatic growth. Methodological challenges—including blinding, expectancy effects, and ADC veridicality—will be addressed alongside ethical considerations for scaling such approaches. This work contributes to ongoing dialogues at the intersection of consciousness science, psychiatry, and contemplative studies. It invites the TSC community to consider: Can rigorously induced altered states redefine the ontological limits of mind and medicine? Future directions include longitudinal multimodal imaging, ADC phenomenology standardization, and hybrid meditation–psychedelic protocols to optimize transformative healing across neuropsychiatric domains.

J. Kim Penberthy, PhD, ABPP, is the Chester F. Carlson Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia School of Medicine and a board-certified clinical psychologist. Her academic and clinical career has focused on developing and evaluating innovative approaches to mental health treatment, with particular expertise in mindfulness-based interventions, persistent depressive disorder, clinician wellness, extraordinary experiences, prolonged grief disorder, and psychedelic-assisted therapy.

Dr. Penberthy received her doctoral training in clinical psychology and has held numerous academic, clinical, research, and leadership positions throughout her career. At the University of Virginia, she is involved in interdisciplinary research examining the psychological, phenomenological, and neurobiological dimensions of grief, consciousness, mindfulness, and psilocybin-assisted treatment. She is currently leading research on the potential use of psilocybin-assisted therapy for prolonged grief disorder and has also contributed to studies of after-death communication and other transformative experiences associated with bereavement and well-being.

Dr. Penberthy has held national leadership roles within the American Psychological Association, including serving as President of the Society of Clinical Psychology, APA Division 12. She has received recognition for her contributions to psychological science, clinical care, teaching, mentorship, professional leadership, and clinician well-being.

An experienced educator and presenter, Dr. Penberthy has delivered invited lectures, workshops, keynote addresses, and conference presentations throughout the United States and internationally. Her presentation topics include mindfulness across the lifespan, persistent depressive disorder, the Cognitive Behavioral Analysis System of Psychotherapy, prolonged grief disorder, psilocybin-assisted therapy, after-death communication, clinician wellness, and the therapeutic potential of altered and extraordinary states of consciousness. Her work bridges clinical psychology, psychiatry, contemplative science, consciousness studies, and emerging psychedelic research, with an emphasis on translating scientific findings into compassionate and meaningful clinical care.